

# Mangalam Drugs and Organics Limited

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413



**REF: MDOL/CS-SE/2023- 24/028**

**November 8, 2023**

**To,**  
Listing Department  
**BSE Ltd**  
1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.  
**Scrip Code: 532637**

Listing Department  
**National Stock Exchange of  
India Limited**  
“Exchange Plaza”, 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051  
**Symbol: MANGALAM**

**Sub: Outcome of Board Meeting held on Wednesday, November 8, 2023**

Dear Sir / Madam,

Pursuant to Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations) we wish to inform that the Board of Directors of the Company at its meeting held today i.e., November 8, 2023 *inter-alia* transacted the following business:

1. Considered & approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023 along with the Limited Review Reports on the results pursuant to Regulation 33 of the Listing Regulations; (Annexure A)

In compliance with the applicable regulations of the SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we declare that Statutory auditors of the Company have issued the reports with unmodified opinion on the un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2023

The meeting of Board of Directors of the Company commenced at 04:00 p.m. and concluded at 07:50 p.m.

We request you to take the same on your records & Oblige.

Thanking You,

Yours faithfully,

**For Mangalam Drugs & Organics Limited**

**Govardhan M. Dhoot**  
**Chairman & Managing Director**  
**DIN: 01240086**



**V. S. SOMANI & CO.**  
**CHARTERED ACCOUNTANTS**

UNIT NO.127, 1ST FLOOR,  
PRABHADEVI UNIQUE INDUSTRIAL  
PREMISES CO-OP SOCIETY LTD.,  
TWIN TOWER LANE,  
OFF. VEER SAVARKAR MARG,  
PRABHADEVI, MUMBAI 400 025.  
PHONE NO: 022 66624558  
EMAIL ID: [vidyadhar@cavssomani.com](mailto:vidyadhar@cavssomani.com)

**Independent Auditor's Review Report on the Quarterly and Half yearly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**The Board of Directors,**  
Mangalam Drugs and Organics Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs and Organics Limited** (the "Company") for the quarter and half year ended September 30, 2023 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. **Conclusion:**  
Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS')




specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For V.S. SOMANI & Co.,**

*Chartered Accountants*

*Firm Registration No. 117589W*



**CA Vidyadhar Somani**

*Proprietor*

Membership No.102664

UDIN No. 23102664BGUQMU4853



Place: Mumbai

Date: November 08, 2023

MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Sr.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A) Part-1 Standalone Statement of Un-Audited Financial Results for the Quarter and Half Year Ended September 30, 2023</b>							
1	<b>Income from Operations</b>						
	(a) Net Sales and Services from Operations	8,136.64	8,700.34	10,798.09	16,836.98	21,744.74	37,019.54
	(b) Other Operating Income	18.91	46.46	34.48	65.37	37.32	205.75
	<b>Total Income from Operations (net) (a+b)</b>	<b>8,155.55</b>	<b>8,746.80</b>	<b>10,832.57</b>	<b>16,902.35</b>	<b>21,782.06</b>	<b>37,225.29</b>
2	<b>Expenses</b>						
	(a) Cost of Materials Consumed	6,689.54	5,966.20	7,324.07	12,655.74	15,541.28	27,744.95
	(b) Purchase of Stock in trade	64.19	0.24	1251.47	64.43	1352.50	1535.52
	(c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade	(1,681.92)	620.72	(1,210.26)	(1,061.20)	(2,134.95)	(4,216.11)
	(d) Employee Benefits Expenses	1,010.83	888.53	954.44	1,899.36	1,890.04	3,461.23
	(e) Depreciation and amortization expenses	373.01	341.86	275.62	714.87	535.63	1,098.89
	(f) Other Expenses	1,853.67	1,618.56	1,669.61	3,472.23	3,252.33	6,147.86
	<b>Total Expenses (a to f)</b>	<b>8,309.32</b>	<b>9,436.11</b>	<b>10,264.95</b>	<b>17,745.43</b>	<b>20,436.83</b>	<b>35,772.34</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(153.77)</b>	<b>(689.31)</b>	<b>567.62</b>	<b>(843.08)</b>	<b>1,345.23</b>	<b>1,452.95</b>
4	Other Income	2.89	1.96	0.05	4.85	0.71	43.56
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items</b>	<b>(150.88)</b>	<b>(687.35)</b>	<b>567.67</b>	<b>(838.23)</b>	<b>1,345.94</b>	<b>1,496.51</b>
6	Finance costs (net)	324.48	341.19	255.50	665.67	609.98	1275.13
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items</b>	<b>(475.36)</b>	<b>(1,028.54)</b>	<b>312.17</b>	<b>(1,503.90)</b>	<b>735.96</b>	<b>221.38</b>
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit/(Loss) from ordinary activities before tax (7-8)</b>	<b>(475.36)</b>	<b>(1,028.54)</b>	<b>312.17</b>	<b>(1,503.90)</b>	<b>735.96</b>	<b>221.38</b>
10	<b>Tax Expenses</b>						
	Current Tax	0	0.00	104.95	0.00	237.96	(2.62)
	Mat Credit Entitlement	10.61		0.00	10.61		0.00
	Deferred Tax	(130.00)	(75.00)	(15.40)	(205.00)	(25.00)	97.00
	<b>Total Tax Expenses (a+b)</b>	<b>(119.39)</b>	<b>(75.00)</b>	<b>89.55</b>	<b>(194.39)</b>	<b>212.96</b>	<b>94.38</b>
11	<b>Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)</b>	<b>(355.97)</b>	<b>(953.54)</b>	<b>222.62</b>	<b>(1,309.51)</b>	<b>523.00</b>	<b>127.00</b>
12	Extraordinary Items	0	0	0	0	0	0
13	<b>Net Profit(+)/Loss (-) for the period(11-12)</b>	<b>(355.97)</b>	<b>(953.54)</b>	<b>222.62</b>	<b>(1,309.51)</b>	<b>523.00</b>	<b>127.00</b>
14	Share of Profit / (Loss) of associates						
15	Minority Interest						
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of</b>	<b>(355.97)</b>	<b>(953.54)</b>	<b>222.62</b>	<b>(1,309.51)</b>	<b>523.00</b>	<b>127.00</b>
17	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	3.12	3.12	2.95	6.24	5.90	12.48
	<b>Total Comprehensive Income (16+17)</b>	<b>(352.85)</b>	<b>(950.42)</b>	<b>225.57</b>	<b>(1,303.27)</b>	<b>528.90</b>	<b>139.48</b>
18	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
19	Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year						13,612.80
20	<b>Earnings Per Share (EPS) (of Rs 10/-each not annualised):</b>						
	(a) Basic	(2.25)	(6.02)	1.41	(8.27)	3.30	0.80
	(b) Diluted	(2.25)	(6.02)	1.41	(8.27)	3.30	0.80




MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Standalone Statement of Assets and Liabilities		
	Rs. in Lacs	
	As at 30.09.2023 Unaudited	As at 31.03.2023 Audited
<b>ASSETS</b>		
<b>A. Non-current Assets</b>		
(a) Property, Plant and Equipment	10552.07	10763.19
(b) Right to use assets	2150.12	1951.66
(c) Capital Work-In-Progress	0.00	640.40
(d) Other Intangible Assets	2015.87	1521.42
(e) Intangible Assets Under Development	358.79	308.49
(f) Financial Assets		
(i) Investments	3.44	0.43
(ii) Other Financial Assets	30.84	30.84
(g) Other Non-current Assets (Capital Advances)	87.37	88.04
<b>Total Non-current Assets (A)</b>	<b>15198.50</b>	<b>15,304.47</b>
<b>B. Current Assets</b>		
(a) Inventories	14052.73	13746.65
(b) Financial Assets		
(i) Trade Receivables	2898.46	4653.29
(ii) Cash and Cash Equivalents	547.99	268.07
(iii) Bank Balance other than Cash and Cash Equivalents	0.76	0.76
(iv) Loans	9.84	4.55
(v) Other Financial Assets	4211.97	729.91
(c) Other Current Assets (Non Financials)	1799.38	1255.18
<b>Total Current Assets (B)</b>	<b>23521.13</b>	<b>20,658.41</b>
<b>TOTAL ASSETS (A + B)</b>	<b>38719.63</b>	<b>35,962.88</b>
<b>EQUITY AND LIABILITIES</b>		
<b>A. Equity</b>		
(a) Equity Share Capital	1582.82	1582.82
(b) Other Equity	12309.53	13612.80
<b>Total Equity (A)</b>	<b>13892.35</b>	<b>15,195.62</b>
<b>B. Non-Current Liability</b>		
(a) Financial Liabilities		
i) Borrowings	1780.73	1876.63
ii) Lease Liabilities	659.87	673.90
ii) Other Financial Liabilities	0.05	0.05
(b) Deferred Tax Liabilities (Net)	1249.15	1451.59
(c) Other Non-Current Liabilities	229.35	229.34
<b>Total Non-current Liabilities (B)</b>	<b>3919.15</b>	<b>4,231.51</b>
<b>C. Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	5765.57	4956.71
(ii) Lease Liability	678.17	721.49
(ii) Trade Payables		
Total Outstanding dues to Micro and small enterprises	1084.03	1109.99
Total Outstanding dues of creditors other than micro and small enterprises	9390.23	8597.28
(iii) Other Financial Liabilities (other than those specified in item (b))	569.00	625.92
(b) Other Current Liabilities	3166.08	352.34
(c) Provisions	218.52	134.44
(d) current tax liabilities	36.53	37.58
<b>Total Current Liabilities (C)</b>	<b>20908.13</b>	<b>16535.75</b>
<b>TOTAL EQUITY AND LIABILITIES (A + B + C)</b>	<b>38719.63</b>	<b>35,962.88</b>



## MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413


Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



## Cash Flow Statement For the Period Ended September 30, 2023

(Rs. In Lacs)

Particulars	For the Period ended Sep 30, 2023 Unaudited	For the Period ended March 31, 2023 Audited
<b>A. Cash flow from operating activities</b>		
Net profit before tax and extra ordinary items.	(1,503.90)	221.38
<b>Add / (Less) :</b>		
Depreciation & amortisation	714.87	1,098.89
Interest expenses (net)	665.67	1,275.13
Dividend Income	(0.04)	(0.05)
(Gain)/loss on sale of fixed assets	(1.81)	0.33
Asset Discarded		
(Gain)/loss on sale of investments		
Prov of Diminution in value of Investment		
Remeasurements of the defined benefit plans	8.80	17.60
<b>Operating profit before working capital changes</b>	<b>(116.41)</b>	<b>2,613.28</b>
<b>Adjustment for :</b>		
(Increase)/decrease in short term loans and advances	(5.29)	(0.95)
(Increase)/decrease in other current assets	(4,026.24)	(40.52)
(Increase)/decrease in trade receivables	1,754.83	(4.28)
(Increase)/decrease in inventory	(306.08)	(2,036.09)
(Increase)/decrease in other non-current assets	0.67	152.96
Increase/(decrease) in trade payables	766.99	4,252.56
Increase/(decrease) in other current liabilities	2,813.73	(190.40)
Increase/(decrease) in provisions	26.11	(1,118.65)
Increase/(decrease) in current lease liabilities	(43.32)	333.82
Increase/(decrease) in non-current liabilities	0.01	(164.54)
Increase/(decrease) in deposits		
Increase/(decrease) in non current lease liabilities	(14.03)	152.50
	<b>967.38</b>	<b>1,336.41</b>
<b>Cash generated from operations</b>	<b>850.97</b>	<b>3,949.70</b>
<b>Add / ( Less) :</b>		
Income Tax (Paid)/ Refund	(10.61)	2.61
<b>Net cash from operating activities</b>	<b>840.36</b>	<b>3,952.31</b>
<b>B. Cash flow from investing activities :</b>		
Purchase of fixed assets including Capital WIP	(608.35)	(2,791.37)
Sale of fixed assets	3.60	574.09
Sale/(Purchase) of investments	(3.01)	-
Divided Income	0.04	0.05
<b>Net cash from investing activities</b>	<b>(607.72)</b>	<b>(2,217.23)</b>
<b>C. Cash flow from financing activities :</b>		
Proceeds/(repayment) of short term borrowing	808.86	247.09
Proceeds/(repayment) of long term borrowing	(95.91)	(633.67)
Interest Paid (net)	(665.67)	(1,275.12)
<b>Net cash used in financing activities</b>	<b>47.28</b>	<b>(1,661.70)</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>279.92</b>	<b>73.38</b>
<b>Cash and cash equivalents - opening balance</b>	<b>268.07</b>	<b>194.69</b>
<b>Cash and cash equivalents - closing balance</b>	<b>547.99</b>	<b>268.07</b>
<b>Details of cash and cash equivalent at the end of the Period / Year</b>		
- Cash in hand	8.92	4.27
- Balance in current and fix deposit accounts	539.07	263.80
<b>Total</b>	<b>547.99</b>	<b>268.07</b>



MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413


Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Notes :

1	The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
2	The above Audited financial results of the Company for the year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company at their meeting held on November 8, 2023.
3	The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
4	The figures for the quarter ended 30th September, 2023 are the balancing figures between the figures in respect of the half year ended 30th September 2023 and the unaudited published figures for quarter ended 30th June 2023.
5	The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.
6	As on september 30 ,2023 , the company has acquired 3010 equity shares of Rs. 100/- each from the shareholders of Mangalam Laboratories Private Limited (MLPL) which is into the business of manufacturing & trading of pharmaceutical products. On acquisition MLPL has become wholly owned subsidiary of the company which is not a material subsidiary.

On behalf of Board of Directors  
For Mangalam Drugs and Organics Limited

  
Shri Govardhan M. Dhoot  
Chairman and Managing Director  
DIN:01240086

Place: Mumbai  
Date: 8 th November , 2023





**Limited Review Report on unaudited consolidated financial results of Mangalam Drugs and Organics Limited for the Half year ended 30<sup>th</sup> September, 2023 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup> August 2021.**

**To the Board of Directors,  
Mangalam Drugs and Organics Limited**


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Mangalam Drugs and Organics Limited** (hereinafter referred to as "the Parent"), its subsidiary (the Parent and its subsidiary together referred to as "the Group") and its share of the net loss after tax and total comprehensive income of its subsidiary for the half year ended from 1<sup>st</sup> April 2023 to 30<sup>th</sup> September 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup> August 2021.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup> August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.



4. The statement includes the results of the Mangalam Laboratories Private Limited a subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10<sup>th</sup> August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of a subsidiary included in the Statement, whose interim financial results reflects total assets (before consolidation adjustments) of Rs. 17,45,08,672 as at 30<sup>th</sup> September, 2023 and total revenues (before consolidation adjustments) of Rs. 2,10,000, total net loss after tax and total comprehensive income (before consolidation adjustments) of Rs. 47,155 for the half year ended 30<sup>th</sup> September, and cash outflows (net) (before consolidation adjustments) of Rs. 1,76,264 for the period from 1<sup>st</sup> April, 2023 to 30<sup>th</sup> September, 2023 as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

**For V.S. SOMANI & Co.,**  
Chartered Accountants  
Firm Registration No. 117589W



**C.A. Vidyadhar Somani**  
Proprietor  
Membership No.102664  
UDIN No. 23102664BGUQMV6649



Place: Mumbai  
Date: November 08, 2023

**MANGALAM DRUGS AND ORGANICS LIMITED - CONSOLIDATED**  
CIN - L24230MH1972PLC116413  
Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

Sr.No	Particulars	Rs. in Lacs
		Half Year Ended
		30.09.2023
		Unaudited
<b>A) Part-1 Consolidated Statement of Un-Audited Financial Results for Half Year Ended September 30, 2023</b>		
1	<b>Income from Operations</b>	
	(a) Net Sales and Services from Operations	16,836.99
	(b) Other Operating Income	65.37
	<b>Total Income from Operations (net) (a+b)</b>	<b>16,902.36</b>
2	<b>Expenses</b>	
	(a) Cost of Materials Consumed	12,655.74
	(b) Purchase of Stock in trade	64.43
	(c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade	(1,061.20)
	(d) Employee Benefits Expenses	1,899.36
	(e) Depreciation and amortization expenses	715.80
	(f) Other Expenses	3,473.87
	<b>Total Expenses (a to f)</b>	<b>17,748.00</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(845.64)</b>
4	Other Income	6.95
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>(838.69)</b>
6	Finance costs (net)	665.67
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>(1,504.36)</b>
8	Exceptional items	0.00
9	<b>Profit/(Loss) from ordinary activities before tax (7-8)</b>	<b>(1,504.36)</b>
10	<b>Tax Expenses</b>	
	Current Tax	0.00
	Mat Credit Entitlement	10.61
	Deferred Tax	(205.00)
	<b>Total Tax Expenses (a+b)</b>	<b>(194.39)</b>
11	<b>Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)</b>	<b>(1,309.97)</b>
12	Extraordinary Items	0
13	<b>Net Profit(+)/Loss (-) for the period(11-12)</b>	<b>(1,309.97)</b>
14	Share of Profit / (Loss) of associates	
15	Minority Interest	
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14-15)</b>	<b>(1,309.97)</b>
17	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	6.24
	<b>Total Comprehensive Income (16+17)</b>	<b>(1,303.73)</b>
18	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82
19	Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year	
20	<b>Earnings Per Share (EPS) (of Rs 10/-each not annualised):</b>	
	(a) Basic	(8.28)
	(b) Diluted	(8.28)



## MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Consolidated Statement of Assets and Liabilities		Rs. in Lacs
		As at 30.09.2023 Unaudited
<b>ASSETS</b>		
<b>A. Non-current Assets</b>		
(a) Property, Plant and Equipment		10589.25
(b) Right to use assets		2150.12
(c) Capital Work-In-Progress		0.00
(d) Other Intangible Assets		2015.87
(e) Intangible Assets Under Development		358.79
(f) Financial Assets		
(i) Investments		0.43
(ii) Other Financial Assets		30.84
(g) Other Non-current Assets (Capital Advances)		104.18
<b>Total Non-current Assets (A)</b>		<b>15,249.48</b>
<b>B. Current Assets</b>		
(a) Inventories		14052.73
(b) Financial Assets		
(i) Trade Receivables		2898.77
(ii) Cash and Cash Equivalents		565.47
(iii) Bank Balance other than Cash and Cash Equivalents		0.76
(iv) Loans		1683.14
(v) Other Financial Assets		1818.41
(c) Other Current Assets (Non Financials)		1799.38
<b>Total Current Assets (B)</b>		<b>22,818.66</b>
<b>TOTAL ASSETS (A + B)</b>		<b>38,068.14</b>
<b>EQUITY AND LIABILITIES</b>		
<b>A. Equity</b>		
(a) Equity Share Capital		1582.82
(b) Other Equity		11655.85
<b>Total Equity (A)</b>		<b>13,238.67</b>
<b>B. Non-Current Liability</b>		
(a) Financial Liabilities		
i) Borrowings		1780.73
ii) Lease Liabilities		659.87
ii) Other Financial Liabilities		0.05
(b) Deferred Tax Liabilities (Net)		1249.15
(c) Other Non-Current Liabilities		229.35
<b>Total Non-current Liabilities (B)</b>		<b>3,919.15</b>
<b>C. Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings		5765.57
(ii) Lease Liability		678.17
(ii) Trade Payables		
Total Outstanding dues to Micro and small enterprises		1084.03
Total Outstanding dues of creditors other than micro and small enterprises		9390.23
(iii) Other Financial Liabilities (other than those specified in item ( C )		569.00
(b) Other Current Liabilities		3168.27
(c) Provisions		255.05
<b>Total Current Liabilities (C)</b>		<b>20910.32</b>
<b>TOTAL EQUITY AND LIABILITIES (A + B + C)</b>		<b>38,068.14</b>



MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.




Notes :

1	The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
2	The above Audited financial results of the Company for the year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company at their meeting held on November 8, 2023.
3	The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
5	The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.
6	Consolidated results includes results of Mangalam Laboratories Pvt Limited ,subsidiary for the purpose of Consolidated results
7	As on september 30,2023 the Mangalam Drugs and Organics Limited has acquired the 3010 shares of Mangalam Laboratories Pvt Limited of Rs. 100 each. Hence Mangalam Laboratories Pvt Limited became wholly owned subsidiary of Mangalam Drugs and Organics Limited .The wholly owned subsidiary is not a material subsidiary of the Mangalam Drugs and Organics Limited
8	Since the Mangalam Laboratories Pvt Limited has become subsidiary as on september 30, 2023 the figures for consolidation for the quarter ended september 30 , 2023 and Balance sheet & cash flow as on March 31 , 2023 is not applicable

Place:Mumbai  
Date: 8 th November , 2023

On behalf of Board of Directors  
For Mangalam Drugs and Organics Limited

  
Shri Govardhan M. Dhoot  
Chairman and Managing Director  
DIN:01240086

